Navigation Links
FDA Panel to Vote on Drugs to Prevent Prostate Cancer
Date:12/1/2010

WEDNESDAY, Dec. 1 (HealthDay News) -- A U.S. Food and Drug Administration advisory panel is expected to decide Wednesday whether to approve two drugs for the prevention of prostate cancer, the third highest cancer killer of men.

Avodart and Proscar, manufactured by GlaxoSmithKline and Merck, respectively, are already approved to treat enlarged prostates. The drug makers say their research shows the drugs also lower the risk of prostate cancer by more than 20 percent.

FDA regulators have several concerns, the Associated Press reported. For one thing, black men, who are at high risk for the disease, were underrepresented in the clinical trials. "The applicability to African-American men is not known due to marked under-representation," the FDA's online review stated.

Blacks made up just 4 percent of Merck's patients and only 2 percent of Glaxo's patients, according to the AP.

The panel of outside experts assembled by the FDA is also likely to discuss the overall value of preventing low-grade tumors. According to the FDA, more than three-quarters of the tumors the drugs prevent are slow-growing, meaning they are non-aggressive and probably not life-threatening for anyone with a life expectancy of less than 20 years.

But even if the tumors aren't aggressive, Glaxo has said they often involve unnecessary treatment and biopsies, or surgical procedures, to diagnose cancer, that pose risks of their own.

Also, slightly more aggressive tumors were seen in men taking Avodart and Proscar, compared with those taking placebo pills, according to the FDA. But the pharamaceutical companies say the drugs simply make those tumors easier to detect because they shrink the prostate.

The U.S. National Cancer Institute estimates that 217,730 men will be diagnosed with prostate cancer this year and 32,050 men will die of it.

The FDA usually follows the recommendations of its expert panels, although it
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
2. Teens Should Get Meningitis Booster Shot: CDC Panel
3. Expert Panel Links Popular Bone Drugs to Rare Fracture
4. FDA Panel to Mull Ban on Diet Drug Meridia
5. Experts Support FDA Panels Backing of New Blood Thinner
6. Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
7. FDA Panel Seems Skeptical Over Key Avandia Data
8. FDA Panel Appears Skeptical Over Key Avandia Data
9. NJIT professor heads panel studying sudden car acceleration
10. FDA Panel Votes Against Approval of Female Viagra
11. FDA Panel Weighs OK of Female Viagra
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... health concerns in the United States, with 32 percent ... 2012. As health problems such as childhood obesity grow, ... the problem. , A new study, led by Jenine ... at Washington University in St. Louis, examined the use ... conversations about the issue of overweight kids. , The ...
(Date:7/10/2014)... For those students looking to bump up their ... be spending more time in a library or study ... University research shows that students who were members of ... during their freshman and sophomore years had higher GPAs ... indicated that students with memberships stayed in school longer. ...
(Date:7/10/2014)... Alba,s research at the University of Huddersfield could help ... popular emulsion-based food products such as butter, mayonnaise, ... to gain an international profile for her work. , ... science at the University and now she has embarked ... supervisor, Dr Vassilis Kontogiorgos, she is investigating the potential ...
(Date:7/10/2014)... at Rutgers University-Newark says the human brain operates much ... finding that could provide a better understanding of schizophrenia, ... afflict an estimated 13.6 million Americans. , In newly ... Cole, an assistant professor at the Center for Molecular ... of a person at rest is basically the same ...
(Date:7/10/2014)... at the Bellvitge Biomedical Research Institute (IDIBELL) and the ... 19 patients a new therapeutic combination to combat resistant ... new treatment could stabilize the growth of these tumors ... Journal of Cancer ., Sarcomas , Sarcomas are ... are several subtypes. It can affect from children to ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Want a higher GPA in college? Join a gym 2Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2
... protein pathway that may hold the secret to understanding ... State University researchers. Anumantha Kanthasamy, a distinguished professor ... R. Lloyd Endowed Chair in Neurotoxicology at the ISU ... the complex mechanisms of the disease for more than ...
... (HealthDay News) -- A new study finds that heart attack ... other heart attack patients to receive priority care at emergency ... patients admitted to 96 hospitals in the province of Ontario ... had a history of depression recorded in their medical charts. ...
... the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory reveals ... compulsively overeat, or binge: In binge eaters but not ordinary ... triggers a spike in dopamine - a brain chemical linked ... February 24, 2011, in the journal Obesity - ...
... is available in German . , More ... a minimally invasive manner. A small incision in the abdominal ... insert the instrument and make the organs visible with an ... body as much as traditional surgeries do. However, these minimally ...
... , MONDAY, Feb. 28 (HealthDay News) -- Cancer ... accompanying muscle loss and malnutrition by taking fish oil ... The finding is based on a small study ... hope that a simple, noninvasive intervention might go a ...
... 70 and older have hearing loss, but those who are ... this loss, according to a new study led by Johns ... online Feb. 28 in the Journal of Gerontology: Medical Sciences, ... survey in older adults on this often ignored and underreported ...
Cached Medicine News:Health News:ISU research raises hope for solving Parkinson's disease puzzle 2Health News:Heart Patients With Depression Often Find ER Delays 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 2Health News:Binge eaters' dopamine levels spike at sight, smell of food 3Health News:Minimally invasive surgeries: Laser suturing 2Health News:Minimally invasive surgeries: Laser suturing 3Health News:Fish Oil Seems to Help Cancer Patients Preserve Muscle 2Health News:Fish Oil Seems to Help Cancer Patients Preserve Muscle 3Health News:Hearing loss rate in older adults climbs to more than 60 percent in national survey 2
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... This user-friendly instrument ... Plasma Protein analyzer for ... It is a well ... reliable results for a ...
For Detection of Bile Component in Reflux Disease...
Medicine Products: